Protalix (PLX) Q4 2025 earnings review
Milestone Cash Masks Underlying Revenue Volatility
Protalix's FY25 results reflect a transition year heavily reliant on lump-sum payments and partner inventory timing. Total revenue remained flat at $52.7M, but net income reversed to a $6.6M loss as R&D spending surged 51% to fund the PRX-115 gout trial. Despite management touting 'strong commercial execution,' core Elfabrio sales to Chiesi actually fell 23%. However, the long-term narrative was saved by the European Commission's approval of the 4-week Elfabrio dosing regimen, unlocking a $25M milestone that dramatically bridges the cash runway to 2026 and drives a massive upward revenue guidance revision.
🐂 Bull Case
The EC approval for a 2mg/kg every-4-weeks Elfabrio dosing regimen triggers a $25M milestone from Chiesi, boosting cash to an estimated $50M by April 2026. This dosing convenience also significantly strengthens the drug's competitive positioning in the EU.
The Phase 2 trial for PRX-115 (uncontrolled gout) is actively enrolling. Management believes this PEGylated uricase can be a best-in-class therapy, representing the company's most significant mid-term value catalyst.
🐻 Bear Case
Elfabrio sales to Chiesi declined $6.8M YoY. Management attributes this to pricing and inventory timing, underscoring the lack of visibility and control Protalix has over end-market commercialization.
Sales to Pfizer spiked $5.6M in FY25 purely due to Pfizer's own manufacturing issues. As this normalizes, FY26 guidance implies a 27% deceleration in the Elelyso franchise.
⚖️ Verdict: ⚪
Neutral. The $25M milestone secures the balance sheet, but the fundamental operating business is showing cracks. The sharp decline in Elfabrio channel sales contradicts the bullish commercial narrative, leaving the company highly dependent on binary R&D outcomes from PRX-115.
Key Themes
Contradictory Commercial Narrative on Elfabrio
Management's opening quote cited 'strong commercial execution with our partners.' The data directly contradicts this: revenues from Chiesi (Elfabrio) dropped from $29.3M in FY24 to $22.5M in FY25 (a 23% decline). The company blamed changes in the average net selling price and 'changes in the quantities the Company sold to Chiesi's inventory.' This lumpiness obscures real patient demand and raises red flags about pricing power in the Fabry market.
EC Approval Transforms Elfabrio's EU Profile
The European Commission approved the every-4-weeks (E4W) dosing regimen for Elfabrio. By cutting infusion frequency by 50% for stable patients, Elfabrio becomes the only ERT with E4W dosing approved in the EU. This is a massive driver for market share expansion and directly triggered the $25M milestone payment.
Elelyso Revenue Pulled Forward
Total FY25 revenue was rescued by a $5.6M unexpected spike in Elelyso sales to Pfizer ($18.2M total), explicitly caused by 'unexpected manufacturing issues' at Pfizer. This is low-quality, non-recurring revenue growth. FY26 guidance projects total Elelyso sales (Pfizer + Brazil) to fall back to $20-23M.
PRX-115 Phase 2 Driving Capital Allocation
The Phase 2 RELEASE trial for PRX-115 (recombinant PEGylated uricase for uncontrolled gout) is now actively enrolling. The trial aims to prove flexible dosing intervals and reduced immunogenicity versus current standards of care. This is the company's primary pipeline focus and the main reason R&D spending surged 51% YoY.
Macro Tax Headwinds Despite Operating Losses
Despite posting a $5.6M pre-tax loss, Protalix recorded $1.0M in income taxes. This structural burden is driven by U.S. Internal Revenue Code Section 174 (from the Tax Cuts and Jobs Act), which requires the capitalization and amortization of R&D expenses, heavily penalizing clinical-stage biotechs by creating phantom taxable GILTI income.
Other KPIs
R&D spending is Accelerating, up 51% from $13.0M in FY24. This reflects the pivot from the commercialized Fabry program toward the expensive Phase 2 clinical trial phase for PRX-115. Management expects this elevated spend rate to continue.
COGS increased 11% YoY ($24.3M to $27.0M) despite total goods revenue slightly declining. This margin compression was driven by the unfavorable mix shift: higher sales of Elelyso to Pfizer (lower margin profile) and lower sales of Elfabrio to Chiesi.
Guidance
Accelerating. The midpoint of $80.5M represents a massive 52% YoY increase compared to FY25's $52.7M. However, this includes the one-time $25.0M milestone. Excluding the milestone, base operating revenue is guided at $53.0M-$58.0M, representing essentially flat growth.
Accelerating. Implies a sharp 51% YoY rebound from FY25's depressed $22.5M. This suggests management expects the inventory destocking issues with Chiesi to clear, and for end-market patient demand to finally translate into wholesale orders.
Decelerating. Represents a 27% drop from the $29.3M achieved in FY25 (Pfizer + Fiocruz combined). This confirms that the FY25 spike driven by Pfizer's manufacturing shortfall was a one-time anomaly.
Key Questions
Chiesi Inventory Dynamics
Elfabrio sales to Chiesi dropped by nearly $7M this year despite claims of strong commercial execution. How much excess inventory is Chiesi currently holding, and exactly when do you expect order volumes to match actual patient prescription growth?
U.S. Label Expansion Timeline
With the E4W dosing regimen now approved in Europe, providing a major competitive advantage, what is the specific timeline and regulatory pathway for Chiesi to submit an application for the E4W regimen to the FDA in the United States?
Elelyso Baseline Run-Rate
Guidance implies a sharp drop in Elelyso sales next year as Pfizer's manufacturing issues resolve. What is the structural, long-term annual revenue floor for the Elelyso franchise across both Pfizer and Fiocruz?